AMAlex Malinowski

Alex Malinowski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alex Malinowski has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BEYOND DOPAMINE BLOCKADE: MUSCARINIC RECEPTOR AGONISM AS A NOVEL THERAPEUTIC STRATEGY IN SCHIZOPHRENIA - A LITERATURE REVIEW OF XANOMELINE-TROSPIUM

    by Przemysław Dominik Drabik, Diana Morawska, Aleksandra Katarzyna Pelczar, Wiktoria Oczkowska, Alex Malinowski, Klaudia Marchewka, Radosław Sochocki, Wiktoria Białek, Agata Sadowska, Emilia Piaszczyńska, et al.

    Background: Schizophrenia is a chronic mental illness affecting over 23 million people worldwide. Current pharmacotherapy, primarily based on dopamine D₂ receptor antagonism, is associated with significant adverse effects - including extrapyramidal symptoms, metabolic disturbances, and hyperprolactinemia - and up to 30% of patients show inadequate response. Aim: This review aims to present and synthesize the available evidence on xanomeline–trospium (Cobenfy®) - the first approved antipsychotic with a predominantly muscarinic mechanism of action - as a novel therapeutic option for schizophrenia. Methods: A narrative literature review was conducted in PubMed, Scopus, Web of Science, and Google Scholar databases up to June 2026, focusing on peer‑reviewed articles, clinical trials, and systematic reviews on xanomeline–trospium in schizophrenia. Results: Xanomeline–trospium demonstrated significant antipsychotic efficacy across the Phase 2 and Phase 3 EMERGENT trials, with moderate‑to‑large effect sizes (Cohen's d = 0.60). The safety profile is distinctly favorable: no extrapyramidal symptoms, weight gain, metabolic disturbances, or prolactin elevation were observed. Gastrointestinal adverse events (nausea, vomiting, constipation) were the most common but were generally mild, transient, and occurred early in treatment. Long‑term open‑label extension studies confirmed sustained efficacy and safety over 52 weeks, with ecological momentary assessment data indicating improvements in real‑world social functioning and positive affect. Conclusions: Xanomeline–trospium represents a promising alternative for schizophrenia treatment, particularly for patients intolerant to conventional antipsychotics or those with metabolic comorbidities. Its novel mechanism and favorable tolerability profile position it as a significant advancement in psychopharmacology. Further research is needed to clarify its role in treatment‑resistant schizophrenia and to confirm long‑term outcomes in diverse populations.

  • Open Access

    PHYSICAL ACTIVITY VS. LOW-GLYCEMIC-INDEX DIET: A COMPARATIVE ANALYSIS OF THEIR EFFECTS ON INSULIN RESISTANCE TREATMENT

    by Klaudia Ostrowicz, Dominika Brzuchacz, Alex Malinowski, Aleksandra Pelczar, Wiktoria Oczkowska, Klaudia Marchewka, Julia Ciesielska, Dawid Furtek, Kacper Bartosik, Joanna Borkowska

    Introduction Insulin resistance is a complex metabolic disorder that plays a pivotal role in the pathogenesis of type 2 diabetes, metabolic syndrome, and cardiovascular diseases. Given its increasing prevalence, growing attention is being directed toward non-pharmacological interventions such as low glycemic index (LGI) diets and regular physical activity. The objective of this study was to compare the effects of an LGI diet and physical activity on the management of insulin resistance. Current State of Knowledge A review of scientific literature published between 2020 and 2025 was conducted using PubMed, Scopus, and Google Scholar databases. Both original research articles and review papers focusing on the impact of LGI diets and physical activity on insulin resistance were included. The findings indicate that both LGI diets and regular physical activity positively influence glycemic parameters by enhancing tissue sensitivity to insulin and reducing blood glucose and insulin concentrations. The combination of these interventions yields superior therapeutic outcomes compared to each intervention alone. The effectiveness of combined strategies also appears to be influenced by the timing and type of physical exercise. Conclusions A multifaceted approach integrating an LGI diet with physical activity constitutes an effective strategy for managing insulin resistance. Given the multifactorial nature of insulin resistance, treatment should be individually tailored and monitored by healthcare professionals. Further research is warranted to account for variables such as sex, age, and duration of the intervention.